Immuneering Corporation (Nasdaq: IMRX) responded to the FDA's approval of a new second-line treatment for metastatic pancreatic cancer, reiterating its ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE